The Rx to OTC Switch: Growth Opportunities for Brand Name Drugs

Jason Chew In the US, patent holders are granted a 20-year term of exclusivity on their inventions. In the pharmaceutical industry, long drug development timelines combined with the Hatch-Waxman act.

Incyte’s Topical JAK Inhibitor: Throw it Over the Counter

Jason Chew Incyte’s topical formulation of its JAK inhibitor, INCB18424, doesn’t seem to get much respect from analysts. Even after showing robust activity and safety in a placebo-controlled multi-dose Phase.

Bringing Innovation Back to Bioscience Research

Jason Chew Innovation is the lifeblood of the economy. Exceptional basic research is crucial to private industry’s success in driving economic growth. This has been true in industries ranging from.

Incyte Pharmaceuticals’ JAK: Just Another Kinase?

Jason Chew With a nearly $2 billion market cap, Incyte is currently the most valuable biotech stock with no marketed product. Is it justified? Practically all of the company’s value.

Seattle Genetics and Immunogen: Fabless Biotechs?

Jason Chew The results are in and it appears Seattle Genetics’ Antibody Drug Conjugate (ADC) technology does indeed work after all- not that it should be a surprise to anyone.

The Rise of China as a Bioscience Leader

Jason Chew The US is far and away the leader in the bioscience industry for now, but under-investment by government and hesitation by the Venture Capital industry may allow other.

Is Pharma Over Invested in Antibody Therapeutics?

Jason Chew There is no doubt that antibody therapeutics have revolutionized medicine in the last decades. Sales of antibody drugs are estimated to be $30 billion in 2009 and expected.

Biotech Startups: Begin With an Exit Plan

Jason Chew According to a 2007 study by the Ewing Marion Kauffman Foundation, a nonprofit devoted to entrepreneurship, 40% of youths between the ages of eight and 21 say they.

Crossing the Valley of Death: From Innovation to Cure

The term “Valley of Death” has come to describe the period of transition when a developing technology is deemed promising, but too new to validate its commercial potential and thereby.

Big Pharma: In-licensing is Not the Cure

Jason Chew(Featured in TheBigRedBiotechBlog, digitalpathologyinsights) Historically, the Big Pharma business model has been that of a fully integrated pharmaceutical company, complete with basic research and development, clinical trials, sales and.

First in Class vs. Best in Class- The Economics of Drug Discovery

The genomics and proteomics revolution has produced thousands of new targets for drug discovery. Designing molecules with novel mechanisms is sexy and can be very rewarding but is risky and.

The Virtualization of Drug Development

Virtual Drug Development has been around since the 1990s with little fanfare. In this model, only the key personnel to manage the core operations of a project are retained, while.

Four Emerging Taiwan Drug Developers

Jason Chew Taiwan’s drug makers have largely focused on generics; few are in the business of developing novel medicines. This is partially due to the large resources required for such.

Taiwan Liposome Company- Ahead of the Pack

Jason Chew Biotechnology is an emerging industry in Taiwan. After the country’s immense success in high tech, the government is searching for another engine of economic growth. There are now.

A Rash of Data Expected From Seattle Genetics

Jason Chew(Featured in FieceBiotech, TheBigRedBiotechBlog) This autumn is turning out to be a busy season for Seattle Genetics. The company is expecting results from up to three clinical trials between.

Teva- Evolution of a Generics Company

Jason Chew(Featured on Bullfax) It is difficult to characterize Teva- is it a generics company or a biopharmaceutical? It would appear it is the best of both worlds, a hybrid.

Big Biotech- The End of An Era

Jason Chew In their heyday, big biotech companies rivaled some Big Pharma companies in market capitalization and epitomized innovation in pharmaceutical development. At the time of its acquistion by Roche,.

GSK and Anthera: Novel Treatments for Cardiovascular Disease

Jason Chew The cardiovascular disease (CVD) market is worth approximately $100 billion today and makes up 12% of all global pharmaceutical sales. Unit sales of medicines for CVD are growing,.

A New Era In HCV Drug Development

Jason Chew(Featured in Pegylated interferon plus ribavirin is the current standard of care for HCV treatment. However, it is a 48-week treatment and is only effective in about 50%.

Vivus Investors Flee to Arena Pharmaceuticals

Jason Chew Vivus shares tanked after an expert panel voted 10 to 6 against approving its obesity drug, Qnexa. The panel was particularly worried that Vivus only had one year data.

Browsing 20 / articles